Clinical Trial

Investigating Glucose Metabolism of LEAP2 With Total-body PET/CT

Study acronym: LEAP2-PET/CT
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The naturally occurring hormone LEAP2 is proposed to have opposite effects to that of the 'hunger hormone' ghrelin. Other that appetite regulation, LEAP2 is involved in glucose metabolism through mechanisms yet not fully understood. With two experimental days; one recieving LEAP2 and one recieving placebo infusion in a randomized order, the study will explore the effect of LEAP2 (vs. placebo) on glucose metabolism through total-body PET/CT-scans and thereby gain a deeper understanding of the ghrelin/LEAP2 system and its interaction with glucose metabolism. Furthermore, the project will generate scanning references in individuals with obesity that are usable in forthcoming research projects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-02; most recent amendment 2025-06-18.
Status change: Recruiting → Active, Not Recruiting 2025-06-18
Trial Details
NCT Number NCT06254365
Lead Sponsor University Hospital, Gentofte, Copenhagen
Conditions Obesity
Enrollment 9 participants
Start Date 2024-02-21
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-06-19